KONTAN.CO.ID - JAKARTA. Pharmaceutical issuer PT Kalbe Farma Tbk (KLBF) is optimistic about achieving double-digit profit growth by 2024. KLBF President Director Vidjongtius said that this year is a year of recovery for Kalbe Farma, after previously recording a decline in the third quarter. KLBF's net profit reached IDR 2.06 trillion in the first nine months of 2023. Kalbe's net profit fell 16.9% compared to the same period last year due to challenging market conditions in the post-pandemic transition period.
Kalbe's optimism aligns with the disruption of the supply chain caused by the Covid-19 pandemic, which has led to high prices for imported raw materials and logistics. “Because we also can't raise prices, that's what temporarily reduced our profit, but this year we are optimistic about recovery,” said Vidjongtius at a groundbreaking event, Wednesday (1/2). Vidjongtius said, to achieve this target, he is preparing a strategy to strengthen sales by releasing innovations and new products. This year, KLBF will issue 15 to 20 new products, including 7 latest medical devices and several generic drugs that are the mainstay of the BPJS program. “These products will certainly support sales and profitability, because generic drugs will always be needed,” he said.
